Ajooni Biotech Limited (NSE: AJOONI) has announced its unaudited financial results for Q3 FY25, reflecting steady revenue growth and financial stability. The company recorded total revenue of ₹2,572.44 lakhs for the quarter ended December 31, 2024, compared to ₹2,005.04 lakhs in Q2 FY25 and ₹2,162.17 lakhs in Q3 FY24, marking an impressive YoY and QoQ growth.

Financial Performance Overview

Ajooni Biotech's financials highlight robust operational efficiency and effective cost management. Net profit for the quarter stood at ₹73.02 lakhs, a significant increase from ₹43.98 lakhs in Q3 FY24. The Earnings Per Share (EPS) was recorded at ₹0.25 for the quarter.

Key Financial Metrics (Q3 FY25 vs Q3 FY24)

• Revenue from operations: ₹2,572.44 lakhs vs. ₹2,162.17 lakhs

• Net profit: ₹73.02 lakhs vs. ₹43.98 lakhs

• Total comprehensive income: ₹115.65 lakhs vs. ₹43.98 lakhs

• Total assets: ₹9,366.94 lakhs vs. ₹4,752.04 lakhs

Segment Performance & Growth Drivers

The company's cost of material consumed stood at ₹2,247.25 lakhs, demonstrating a stable supply chain and efficient production processes. Employee benefit expenses remained under control at ₹70.31 lakhs, ensuring optimized workforce efficiency.

Ajooni Biotech continues to invest in R&D and product innovation, which has contributed to improved financial performance. Total other comprehensive income stood at ₹54.14 lakhs, indicating strong non-operating gains.

Balance Sheet & Assets Growth

As of December 31, 2024, Ajooni Biotech reported total assets worth ₹9,366.94 lakhs, a major jump from ₹4,752.04 lakhs in March 2024. The increase reflects ongoing expansion and investment strategies. Key assets include:

• Property, Plant & Equipment: ₹1,146.86 lakhs

• Inventories: ₹2,089.27 lakhs

• Trade receivables: ₹2,179.63 lakhs

Regulatory Compliance & Auditor's Review

The company remains fully compliant with SEBI (LODR) Regulations, 2015, ensuring transparency in financial reporting. Independent auditors Narinder Kumar & Co. have reviewed the financial statements, stating that there are no material misstatements and the results fairly represent the company’s financial position.

Investor Outlook & Future Plans

Ajooni Biotech Limited's financial results demonstrate steady growth and resilience, positioning the company for future expansion. Investors and stakeholders can expect sustained performance, backed by the company's strong fundamentals and strategic investments.

The Upcoming IPOs in this week and coming weeks are Quality Power Electrical Equipments, L.K. Mehta, Shanmuga Hospital.

The Current active IPO are PS Raj Steels, Voler Car, Maxvolt Energy, Hexaware Technologies, Ajax Engineering, Chandan Healthcare.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.